[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:primary-peritoneal-cancer:brca1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Primary Peritoneal Cancer","BRCA1 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06580314","Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.331227Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07564141","Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer",[12],"2026-08-26T02:16:39.977107Z","2026-07-19T19:36:05.140343Z"]